Morphotek - Articles and news items

First patient enrolled in trial of amatuximab in mesothelioma

Industry news / 18 November 2015 / Victoria White

Amatuximab is a monoclonal antibody (mAb) that triggers antibody-dependent cellular cytotoxicity against tumour cells expressing mesothelin…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+